par Gerlier, L.;Lamotte, Mark;Awada, Ahmad ;Bosly, André;Bries, G.;Cocquyt, Veronique;Focan, Christian;Henry, Sarah;Lalami, Yassine ;Machiels, Jean Pascal;Mebis, J.;Straetmans, N.;Verhoeven, D.;Somers, L.
Référence BMC cancer, 10, page (642)
Publication Publié, 2010
Référence BMC cancer, 10, page (642)
Publication Publié, 2010
Article révisé par les pairs
Résumé : | The use of chemotherapy regimens with moderate or high risk of febrile neutropenia (defined as having a FN incidence of 10% or more) and the respective incidence and clinical management of FN in breast cancer and NHL has not been studied in Belgium. The existence of a medical need for G-CSF primary and secondary prophylaxis with these regimens was investigated in a real-life setting. |